Mitoxantrone, More than Just Another Topoisomerase II Poison

@article{Evison2016MitoxantroneMT,
  title={Mitoxantrone, More than Just Another Topoisomerase II Poison},
  author={Benny J. Evison and B. Sleebs and K. Watson and D. Phillips and S. Cutts},
  journal={Medicinal Research Reviews},
  year={2016},
  volume={36}
}
Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is commonly applied in the treatment of breast and prostate cancers, lymphomas, and leukemias. A comprehensive overview of the drug's molecular, biochemical, and cellular pharmacology is presented here, beginning with the cardiotoxic nature of its predecessor doxorubicin and how these properties shaped the pharmacology of mitoxantrone itself. Although mitoxantrone is… Expand
Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations
Topoisomerases as anticancer targets.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 338 REFERENCES
Mitoxantrone affects topoisomerase activities in human breast cancer cells.
NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform*
Clinical applications of anticancer drugs targeted to topoisomerase II.
  • K. Hande
  • Medicine
  • Biochimica et biophysica acta
  • 1998
The anthracyclines: will we ever find a better doxorubicin?
  • R. Weiss
  • Medicine
  • Seminars in oncology
  • 1992
Toxicity of the topoisomerase II inhibitors
  • K. Seiter
  • Medicine
  • Expert opinion on drug safety
  • 2005
...
1
2
3
4
5
...